Response duration and transfusion requirements. (A) Per patient response, survival events, and duration are depicted in a swimmer plot. The patients are grouped by disease state and treatment. Reasons for no response assessment are as follows: 1 discontinued drug on day 32 due to physician’s decision to initiate a prohibited medication; 1 developed pneumonia (unrelated to study drug) on day 22, leading to respiratory failure and death; and 1 had an AE on day 45 and discontinued drug and never resumed or underwent any assessments before dropping from the study at 10 months. (B) RBC transfusion requirements at baseline (left) and after baseline (right). Eight of 13 patients (62%) requiring RBC transfusions at study entry achieved 56-day RBC TI; 3 of 13 (23%) remained RBC transfusion dependent; and 2 of 13 (15%) were not evaluated. Maintenance of RBC TI from baseline to postbaseline occurred in 8 of 9 patients (89%). (C) Platelet transfusion requirements at baseline (left) and postbaseline (right). Six of 9 patients (67%) requiring platelet transfusions at baseline achieved 56-day platelet TI; 1 of 9 (11%) remained platelet transfusion dependent; and 2 of 9 (22%) were not evaluated. Maintenance of platelet TI from baseline to postbaseline occurred in 11 of 13 patients (85%). Asterisk (∗) indicates received lower than optimal dose (≤50%) of OLU; ◊ indicates patient was started on suboptimal dose of monotherapy, then added AZA to regimen; HSCT, proceeded to HSCT after remission.